Forte Biosciences Plunges 12.62% Post Reverse Split

On August 8, 2025, Forte Biosciences experienced a significant drop of 12.62% in pre-market trading, marking a notable decline in its stock performance.

Forte Biosciences recently conducted a 1-for-25 reverse stock split, which means shareholders now hold one share for every 25 shares they previously owned. This move is often undertaken to boost the stock price and attract more investors, but it can also lead to volatility as the market adjusts to the new share structure.

Additionally, recent SEC filings reveal that Boothbay Fund Management, LLC and Ari Glass, who are associated with the company, collectively own 53,791 shares, representing 0.8% of the total shares. This information is part of a broader filing that outlines the ownership and voting rights of these entities, providing transparency into the company's shareholder structure.